Post-operative Dental Pain Study Comparing Two Different Dosage of Analgesic Efficacy

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT01075243
First received: February 23, 2010
Last updated: January 24, 2013
Last verified: November 2011
  Purpose

GlaxoSmithKline will be conducting this trial to compare analgesic efficacy of paracetamol 1000 mg vs 650 mg. The post-surgical dental pain model will be used to evaluate the analgesic efficacy of paracetamol. Each subject will be enrolled in the study for up to six weeks. The duration of the entire study will be approximately 18 weeks. Each subject will have to come to the clinic for three visits (Screening, Treatment and Follow up visits).


Condition Intervention Phase
Post-surgical Dental Pain
Drug: Paracetamol 1000 mg
Drug: Paracetamol 650 mg
Drug: Placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Study to Compare the Analgesic Efficacy of Two Different Paracetamol Doses as Measured by Post-operative Pain Relief

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Sum of Pain Relief and Pain Intensity Differences from 0 to 6 hours (SPRID 6 hours) [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    SPRID: sum of pain intensity difference (PID) and total pain relief (TOTPAR) at each post-dosing time point. PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [no pain] to 100 [worst possible pain]) from the baseline score. TOTPAR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief).


Secondary Outcome Measures:
  • Time to confirmed first perceptible relief [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

  • Time to onset of meaningful pain relief [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    Participants recorded the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

  • Time to start using rescue medication [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    Median time of use of rescue medication by participants.

  • Proportion of participants with confirmed first perceptible relief [ Time Frame: 1 hour, 2 hours post dose ] [ Designated as safety issue: No ]
    Participants recorded the time to first perceptible relief by starting the first stopwatch at the time of dosing and stopping it when he/she experienced the first perceptible pain relief. The first perceptible pain relief was confirmed if the participant also stopped the second stopwatch indicating meaningful relief.

  • Proportion of participants with meaningful pain relief [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    Participants evaluated the time to meaningful relief by stopping a second stopwatch when they first began to experience meaningful relief.

  • SPRID at 2 hours and 4 hours [ Time Frame: Baseline, 2 hours, 4 hours post dose ] [ Designated as safety issue: No ]
    SPRID: Time weighted sum of PRID over 2 hours and 4 hours. PRID: sum of PID and TOTPAR at each post-dosing time point. PID was derived by subtracting the pain severity score at a given post-dosing time point (pain severity score range 0 [no pain] to 100 [worst possible pain]) from the baseline score. TOTPAR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief).

  • Total pain relief score (TOTPAR) [ Time Frame: Baseline, 2 hours, 4 hours, 6 hours post dose ] [ Designated as safety issue: No ]
    TOTPAR: time-weighted sum of pain relief over 2, 4, and 6 hours. Pain relief was evaluated at different time points during the study up to 6 hours, and immediately after taking rescue medication (if necessary). TOTPAR was assessed on 5-point categorical pain relief rating scale (0=No relief to 4=Complete relief).

  • Proportion of participants who took rescue medication [ Time Frame: 2 hours, 6 hours post dose ] [ Designated as safety issue: No ]
    Percentage of participants who received rescue medication at different time points post dose.

  • Sum of Pain intensity difference (SPID) scores [ Time Frame: Baseline, 2 hours, 4 hours, 6 hours post dose ] [ Designated as safety issue: No ]
    SPID: time-weighted sum of PID over 2, 4 and 6 hours. PID was derived by subtracting the pain severity score at a given post-dosing time point from the baseline score. Pain severity score ranged from 0 - no pain to 100 -worst possible pain.

  • Participants Global Assessment to response to treatment (PGART) [ Time Frame: Baseline to 6 hours post dose ] [ Designated as safety issue: No ]
    PGART was measured by a score in a scale from 0-4: 0- Poor; 1- Fair 2- Good; 3- Very Good; 4- Excellent.


Enrollment: 440
Study Start Date: November 2009
Study Completion Date: March 2010
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Paracetamol 1000mg
Paracetamol 1000mg
Drug: Paracetamol 1000 mg
Paracetamol 1000mg
Experimental: Paracetamol 650 mg
Paracetamol 650 mg
Drug: Paracetamol 650 mg
Paracetamol 650 mg
Placebo Comparator: Placebo
Placebo
Drug: Placebo
Placebo

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects aged 18 to 45 years with moderate-to-severe dental pain as assessed by verbal rating scale (VRS) and confirmed by a score of at least 50 mm out of 100 mm using a visual analogue (VAS) following the surgical removal of up to two mandibular third molars. If only one mandibular third molar is removed, it must be a full bony impaction. If two mandibular third molars are removed, both may be partial bony impactions OR there may be a combination of one full bony impaction with the second tooth being erupted, soft tissue impaction, or partial bony impaction. Ipsilateral maxillary third molars may be removed at the surgeon's discretion, regardless of impaction level.

Exclusion Criteria:

-

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01075243

Locations
United States, Utah
Jean Brown Research
Salt Lake City, Utah, United States, 84124
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT01075243     History of Changes
Other Study ID Numbers: A4000685
Study First Received: February 23, 2010
Last Updated: January 24, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by GlaxoSmithKline:
paracetamol
dental pain
Post-surgical dental pain

Additional relevant MeSH terms:
Toothache
Tooth Diseases
Stomatognathic Diseases
Facial Pain
Pain
Signs and Symptoms
Acetaminophen
Analgesics
Antipyretics
Physiological Effects of Drugs
Pharmacologic Actions
Analgesics, Non-Narcotic
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on July 24, 2014